

# The prevalence of folate-remedial MTHFR enzyme variants in humans

Nicholas J. Marini<sup>\*†</sup>, Jennifer Gin<sup>\*</sup>, Janet Ziegler<sup>‡</sup>, Kathryn Hunkapiller Keho<sup>‡</sup>, David Ginzinger<sup>\*§</sup>, Dennis A. Gilbert<sup>‡</sup>, and Jasper Rine<sup>\*†</sup>

<sup>\*</sup>Department of Molecular and Cellular Biology, California Institute for Quantitative Biosciences, Stanley Hall, University of California, Berkeley, CA 94720-3220; and <sup>‡</sup>Applied Biosystems, Inc., 850 Lincoln Centre Drive, Foster City, CA 94404

Communicated by Bruce N. Ames, University of California, Berkeley, CA, March 24, 2008 (received for review November 20, 2007)

Studies of rare, inborn metabolic diseases establish that the phenotypes of some mutations in vitamin-dependent enzymes can be suppressed by supplementation of the cognate vitamin, which restores function of the defective enzyme. To determine whether polymorphisms exist that more subtly affect enzymes yet are augmentable in the same way, we sequenced the coding region of a prototypical vitamin-dependent enzyme, methylenetetrahydrofolate reductase (MTHFR), from 564 individuals of diverse ethnicities. All nonsynonymous changes were evaluated in functional *in vivo* assays in *Saccharomyces cerevisiae* to identify enzymatic defects and folate remediability of impaired alleles. We identified 14 nonsynonymous changes: 11 alleles with minor allele frequencies <1% and 3 common alleles (A222V, E429A, and R594Q). Four of 11 low-frequency alleles affected enzyme function, as did A222V. Of the five impaired alleles, four could be restored to normal functionality by elevating intracellular folate levels. All five impaired alleles mapped to the N-terminal catalytic domain of the enzyme, whereas changes in the C-terminal regulatory domain had little effect on activity. Impaired activity correlated with the phosphorylation state of MTHFR, with more severe mutations resulting in lower abundance of the phosphorylated protein. Significantly, diploid yeast heterozygous for mutant alleles were impaired for growth, particularly with lower folate supplementation. These results suggested that multiple less-frequent alleles, in aggregate, might significantly contribute to metabolic dysfunction. Furthermore, vitamin remediation of mutant enzymes may be a common phenomenon in certain domains of proteins.

nutrigenetics | polymorphism | vitamin

The ability of enzyme cofactors to remedy metabolic disease-causing mutations has been well documented over the last four decades (for overviews of the field, see refs. 1 and 2). In many cases, the etiological lesion results in a missense change in a cofactor-dependent enzyme, resulting in disruption of a single metabolic step. Subsequent administration of therapeutic doses of the cognate cofactor restores some activity of the mutant enzyme, leading to clinical improvement. Cofactor-remedial mutations occur in many different enzymes that use various cofactors (2). For example, there are numerous vitamin B<sub>6</sub> (pyridoxine)-responsive disorders that result from mutations in specific B<sub>6</sub>-dependent enzymes (2, 3). In addition, the phenylalanine hydroxylase (PAH) cofactor tetrahydrobiopterin (BH<sub>4</sub>) can be used to treat phenylketonuria caused by several different missense mutations in PAH (4). The molecular mechanisms that underlie clinical remediation are the ability of elevated levels of cofactor to either overcome binding defects of K<sub>m</sub> mutants (2) or to serve as a chemical chaperone to improve folding and/or stability of mutant enzyme variants (2–5).

Perhaps the best-studied case is the common folate-remedial polymorphism (677C→T; A222V) of 5,10-methylenetetrahydrofolate reductase (MTHFR; ref. 6). For this enzyme, folate is not a cofactor in the traditional sense but instead controls the level of the substrate 5,10-methylenetetrahydrofolate. The A222V change reduces MTHFR activity and increases its thermolability, which can lead to lower levels of serum folate, increased levels of plasma

homocysteine, and genomic DNA hypomethylation, particularly in those with a diet low in folate (reviewed in ref. 7). Biochemically, the A222V variant may be less tightly bound to its flavin cofactor and more prone to dissociation into monomers but can be stabilized by reduced folates (8, 9).

Because the A222V variant can affect clinical biomarkers, such as serum homocysteine, and can be modulated by folate levels, this allele has been the subject of many epidemiological disease studies for which these biomarkers may be risk factors and for which folate is thought to be chemopreventive or therapeutic [e.g., neural tube defects (NTDs) (10), cardiovascular disease (ref. 11, but see ref. 12), and colon cancer (13)]. However, genetic association of the A222V allele to disease within all these clinical settings has not been consistent (10–14).

Among the issues that can confound association studies (15), the gene–nutrient interaction between A222V activity and folate status may affect the outcome and conclusions of such studies. Indeed, A222V is a risk factor for colon cancer when dietary folate intakes are low but may actually be protective when folate intakes are elevated (13). A second issue relevant to our work is the recent appreciation of the importance of low frequency (allele frequency <1%) nonsynonymous variants as potential genetic determinants in common diseases such as cardiovascular disease and obesity (16–18). However, the potential confounding influence of low frequency variants to disease susceptibility has not been addressed in most association studies.

We have used MTHFR as a prototype vitamin-dependent enzyme to answer several questions about the occurrence and biochemical impact of low-frequency variation in coding regions, and most importantly, the prevalence of folate-remediation of functionally impaired alleles. To this end, we sequenced the MTHFR coding region from >500 individuals of diverse ethnicities and determined the biochemical impact of all nonsynonymous changes as a function of intracellular folate status by complementation in the yeast *S. cerevisiae*. The results established that many nonsynonymous substitutions decreased the function of the enzyme and that folate-remediation of impaired alleles was surprisingly common. Furthermore, because cells heterozygous for MTHFR variants displayed quantitative defects, the aggregate frequencies of individually rare alleles may contribute to common phenotypes.

## Results

**MTHFR Variants in Humans.** The entire coding region of human MTHFR was sequenced by amplifying the coding portion in each

Author contributions: N.J.M., D.A.G., and J.R. designed research; N.J.M., J.G., J.Z., and K.H.K. performed research; J.Z., K.H.K., D.G., and D.A.G. contributed new reagents/analytic tools; N.J.M., J.G., J.Z., K.H.K., D.G., D.A.G., and J.R. analyzed data; and N.J.M. and J.R. wrote the paper.

The authors declare no conflict of interest.

<sup>†</sup>To whom correspondence may be addressed. E-mail: nmarini@berkeley.edu or jr@berkeley.edu.

<sup>§</sup>Present address: Linkage Biosciences, 2503 Bush Street, San Francisco, CA 94115.

This article contains supporting information online at [www.pnas.org/cgi/content/full/0802813105/DCSupplemental](http://www.pnas.org/cgi/content/full/0802813105/DCSupplemental).

© 2008 by The National Academy of Sciences of the USA

**Table 1. Spectrum of nonsynonymous MTHFR alleles observed from sampling >500 unselected individuals of diverse ethnicities**

Exon	Length, bp	Alleles sequenced	Variant	Occurrences*	dbSNP rs no.
1	236 <sup>†</sup>	1,070	None		
2	239	1,016	M110I	1	Previously unrecognized
			R134C	1	45550133
3	111	1,068	None		
4	194	1,050	A222V	308	1801133
			H213R	1	Previously unrecognized
			D223N	1	Previously unrecognized
5	251	1,056	D291N	1	Previously unrecognized
6	135	1,042	None		
7	181	1,062	E429A	251	1801131
			G422R	3	45571736
8	183	1,058	None		
9	102	1,072	R519C	2	45496998
			R519L	2	Previously unrecognized
10	120	1,072	M581I	1	45590836
11	219 <sup>†</sup>	1,076	R594Q	47	2274976
			T653M	4	35737219
			Q648P	1	Previously unrecognized

\*Genotypes of individual Coriell samples at all nonsynonymous loci can be found in [Dataset S1](#).

<sup>†</sup>For exons 1 and 11, only the length of the coding portion of the exon is given.

of 11 exons from 564 individuals of diverse ethnicities. The lengths of the coding regions, the number of alleles interrogated, and all nonsynonymous substitutions are listed in Table 1. In all, we analyzed 2,081,106 bp of coding DNA and sampled every exon to a depth of >1,000 alleles. These data revealed 14 nonsynonymous changes, 11 of which show a minor allele frequency (MAF) <1%, with seven alleles seen only once. Some low-frequency alleles were seen previously (dbSNP entry in Table 1). The number of low-frequency nonsynonymous substitutions was in good agreement with other studies that sampled deeply into random populations (19–21). In addition, three well studied common substitutions were observed that displayed the expected global population frequencies (A222V, 29.3%; E429A, 23.6%; R594Q, 4.4%).

As a quality-control check on the accuracy of the base-calling, we reanalyzed eight variants (including four singletons) by TaqMan allelic-discrimination assays in 100 samples that were independently PCR amplified and saw 100% concordance of the data. Furthermore, population genotyping data from the Environmental Genome Project ([www.niehs.nih.gov/envgenom/](http://www.niehs.nih.gov/envgenom/)) and Perlegen, which both used Coriell Institute Cell Repository (Camden, NJ) samples that overlap some in this study (dbSNP build 128) were in concordance in 814 of 817 (99.6%) genotype calls. For two of the three discordant loci, our sequence data were unambiguous and appeared correct.

We obtained complete coding region sequence for 480 individuals. Eighteen (4%) were carriers of a low-frequency nonsynonymous variant. Significantly, the combination of the three common polymorphisms (A222V, E429A, and R594Q) with the range of the low frequency changes led to a great deal of individual heterogeneity. We observed 28 different nonsynonymous genotypes in this group whose haplotype, in most cases, could not be deduced from the data. The genotypes of individual Coriell samples at all nonsynonymous variant loci are included in [supporting information \(SI\) Dataset S1](#).


**MTHFR-Folate Interaction *In Vivo*.** Because the clinical significance of genetic variants lies in their functional consequence, we tested all nonsynonymous changes for their effect on MTHFR function, and importantly, whether impaired alleles displayed folate responsiveness. The assay is based on complementation of *met13*, which

encodes yeast MTHFR, by human MTHFR (22) but with a modification that allowed us to study the gene–nutrient interaction between MTHFR and folate. Thus, we introduced folate auxotrophy (*fol3*) into a *met13* strain, allowing titration of intracellular folate concentrations by varying folinic acid in the growth media. Folinic acid (5-formyl-tetrahydrofolate) can be metabolized in yeast to methenyl-tetrahydrofolate, which in turn can be converted to other folate coenzymes (23). In this way, we measured human MTHFR functionality (growth in the absence of methionine) as a function of increasingly limiting cellular folate status.


Under these conditions, folinic acid supplementation >50  $\mu\text{g/ml}$  did not confer any significant growth advantage (Fig. 1*a*). However, at concentrations <50  $\mu\text{g/ml}$ , growth clearly correlated with available folinic acid in the medium. Thus intracellular folate levels were rate limiting in this range. When compared to growth of *FOL3* cells, folinic acid supplementation did not completely compensate for lack of endogenous folate biosynthesis. However, this gap was mostly reflected in the density at which cells entered stationary phase rather than growth rate, perhaps reflecting limitations in folinic acid uptake or in the utilization of folinic acid as the sole folate source.

The ability of human MTHFR to complement *fol3 met13* cells was a function of folinic acid supplementation in the media (Fig. 1*b*). As for folate supplementation, expression of human MTHFR from the *GAL1* promoter did not completely compensate for loss of Met13p (compare Fig. 1*b* with *fol3 MET13* cells at equivalent folate doses in Fig. 1*a*). Thus, when folinic acid was <50  $\mu\text{g/ml}$ , both folate and MTHFR were rate limiting for growth, allowing even subtle changes in MTHFR activity to be reflected in the growth readout. Note that folinic acid supplementation of >50  $\mu\text{g/ml}$  did not confer a significant growth advantage to cells expressing either the endogenous yeast MTHFR (*MET13*; Fig. 1*a*) or the major human allele (Fig. 1*b*) but was beneficial for impaired alleles of MTHFR (see below).

**Functional Impact of MTHFR Variants.** Five nonsynonymous alleles tested over a range of folate concentrations illustrated the range of functional effects observed (Fig. 2*a*). There was nearly complete restoration of function of the A222V variant at 100  $\mu\text{g/ml}$  folinic acid and significantly less activity (relative to the major allele) at a




**Fig. 1.** Effects of folinic acid supplementation on growth rate of *fol3Δ* cells and cellular activity of human MTHFR. (a) Growth of *fol3Δ MET13* haploid yeast was measured in 96-well plates as described in *Materials and Methods*. Media was supplemented with folinic acid at the indicated concentrations. The curve labeled *FOL3 (FOL3 MET13)* was from growth in medium without folinic acid. (b) Growth of *fol3Δmet13Δ* haploid yeast transformed with pHMTHFR in media lacking methionine and supplemented with folinic acid at the indicated concentrations. Three independent transformants were tested at each folinic acid concentration to test reproducibility. The curve labeled *met13Δ* represented a single isolate of cells, which were transformed with empty vector and grown at 50  $\mu\text{g/ml}$  folinic acid.



**Fig. 3.** Enzyme activity of MTHFR variants. Crude yeast extract from cells transformed with the indicated MTHFR constructs was prepared and assayed for MTHFR activity as described in *Materials and Methods*. Heat treatment for the indicated times was done on reactions before addition of radiolabeled substrate. Measurements were averages of two independent sets of triplicate assays; error bars indicate standard deviations for the six data points.

$\mu\text{g/ml}$  folinic acid (Fig. 3). Thus, the behavior of A222V in yeast recapitulated its behavior in human cells.

Four low-frequency alleles were tested in the same way (Fig. 2a). R519C appeared benign because growth was unaffected at all folate concentrations. R134C was severely impaired at all folate concentrations, although activity was somewhat folate-responsive. The D223N and M110I alleles displayed folate-remedial activity similar to A222V (although less severely impaired) in that growth was similar to the major allele at  $\geq 50 \mu\text{g/ml}$  folinic acid, but functioned poorly at  $< 50 \mu\text{g/ml}$  folinic acid.



**Fig. 2.** Functional impact and folate remediability of nonsynonymous MTHFR population variants. (a) Six MTHFR variants were tested for the ability to rescue *fol3Δ met13Δ* cells in media lacking methionine at three different folinic acid concentrations. The M110I allele and the M110I A222V doubly substituted allele were tested only at 50 and 25  $\mu$ g/ml folinic acid. The curve labeled Major corresponds to the most common MTHFR allele in the population. Each curve is from a pool of three to six independent transformants. (b) Schematic of the MTHFR protein (656 aa) divided into a N-terminal catalytic domain and a C-terminal regulatory domain of nearly equal size (25). Positions of all nonsynonymous changes are indicated. Benign changes are in green. Changes numbered 1–4 represent folate-remedial alleles indicated in increasing order of severity. Change 5 (R134C) was nearly loss-of-function and not designated as folate remedial (see *Results*) but was somewhat folate augmentable.




containing two (or more) substitutions. Therefore we created several compound alleles (based on their occurrence in individual samples) to test whether allele combinations lead to synergistic or suppressive effects. For A222V combinations with common variants (A222V E429A and A222V R594Q), we observed minor allele homozygotes for at least one of the alleles and therefore are sure that such variants exist. However, for the low frequency variants, both the A222V variant and the novel variants always occurred as heterozygotes. Because we do not know haplotype, these individuals could harbor either the two single substitution alleles or a compound allele. Therefore we created all possible double-substitution alleles and tested their function (e.g., M110I A222V; Fig. 2*a*). At the two folinic acid concentrations tested, the M110I A222V variant functioned more poorly than the sum of the individual alleles, indicating synergistic defects in compound alleles. At 50  $\mu$ g/ml folinic acid, the M110I variant was nearly indistinguishable from the major allele, yet it significantly enhanced the A222V defect. For all combinations tested, alleles that affected function individually (M110I and D291N) synergized when combined with A222V, whereas benign changes did not enhance the A222V defect.

**Biochemical Assays Recapitulated *in Vivo* Function.** To evaluate the reliability of the growth assay, we performed cell-free MTHFR enzyme assays for all variants in crude yeast lysates (see *Materials and Methods*). In addition to measuring specific activity, variants were tested for thermolability (a measure of enzyme stability) by heat treatment at 55°C for various times. There was a good correlation between intrinsic activity and growth rate (Fig. 3; compare the activities of non-heat-treated samples for the major MTHFR allele, A222V and R134C with the growth curves in Fig. 2). Again, the A222V variant displayed  $\approx 50\%$  of the enzymatic activity of the major allele, as reported previously (19, 22, 24). As in the growth assay, the R519C variant exhibited similar activity to the major allele and was representative of all changes in the regulatory domain including the common E429A variant, further indicating changes in this region were benign (data not shown).

The A222V mutant enzyme is less stable and more thermolabile than the major form (8, 9), and folate remediation of this variant is thought to occur by promoting stabilization of the protein. Under the conditions used here (55°C, 20 min), A222V lost nearly all activity, whereas the major allele retained  $\approx 30\%$  of its original activity, in agreement with previous studies (22). The previously unrecognized D223N allele also displayed increased thermolability that may similarly explain folate remediation in this case, although the enzyme defect was not as great.

**Heterozygote Phenotypes.** Because low-frequency alleles usually occur as heterozygotes, their significance tends to be dismissed. To understand better the functional significance of heterozygosity of MTHFR alleles, we created diploid yeast with two copies of human MTHFR by mating haploid strains that each have either the same allele expressed from an integrated expression cassette (homozygotes) or different alleles to create heterozygotes (see *Materials and Methods*). As above, these strains were tested for growth as a function of folate supplementation (Fig. 4). Heterozygotes displayed a growth phenotype in this assay that was exacerbated under conditions of limiting folate, indicating that the reduced-function alleles were codominant with wild type.


Cellular MTHFR activity as measured in the growth assay appeared to reflect additive effects of alleles. Furthermore, additional experiments with hemizygotes (diploids with a single integrated expressed allele; data not shown) demonstrated that the formation of heterodimers between major and minor alleles in heterozygotes offered little or no rescue of mutant alleles. For example, diploid MTHFR major allele/null cells (hemizygotes) behaved similarly to major allele/R134C heterozygotes under all conditions and similarly to major allele/A222V heterozygotes in low



**Fig. 4.** Heterozygote phenotypes for MTHFR variants as recapitulated in yeast. Homozygosity or heterozygosity of MTHFR alleles was recreated in diploid yeast for the major, R134C, and A222V alleles as described in *Materials and Methods*. Diploids were obtained from the mating of haploid strains that each expressed a single allele of MTHFR integrated in the genome. Growth as a function of folinic acid supplementation was assayed exactly as for haploids.

folate media (where A222V is inactivated). Thus, the phenotypic contribution of deleterious alleles in heterozygote cells was easily observed, raising the possibility of more widespread phenotypic consequences from heterozygosity in the human genome.

**Modification of MTHFR Variants in Yeast by Phosphorylation.** The abundance of MTHFR variant proteins was determined by immunoblotting by using antibodies directed against the N-terminal hemagglutinin A (HA) epitope tag (Fig. 5*a*). In all samples, the protein ran as a doublet of  $\approx 72$  kD and 78 kD. This pattern closely resembled that observed for human MTHFR expressed in insect cells (26), where the upper band represents MTHFR multiply-phosphorylated near the N terminus. Phosphorylation of MTHFR in insect cells depends on a threonine residue at position 34, and substitution of this threonine to alanine (T34A) results in an enzyme that is unable to be phosphorylated (26). This mutation had



**Fig. 5.** Immunoblot of human MTHFR variants expressed in yeast. (a) Extracts were made from yeast cells carrying different MTHFR alleles and detected with anti-HA antibody as in *Materials and Methods*. A222V M110I was a doubly substituted allele; Major indicates the most common MTHFR allele in the population. The two rightmost lanes were, side-by-side, the major allele and the nonphosphorylatable T34A mutant (26). (b) The ratio of signal intensities of the unphosphorylated lower band to the phosphorylated upper band for all variants of MTHFR identified in this study plotted as a function of increasing severity of functional impact. Alleles on the x axis were classified as benign or rank ordered with respect to activity. All benign alleles (including the Major allele and all regulatory domain changes) were plotted and show nearly identical ratios of the two MTHFR species, thus the symbols overlapped.



**MTHFR Exon Sequencing.** Eleven MTHFR coding exons were sequenced in the above samples by PCR sequencing using primer pairs commercially available from the Variant SeqR product line (Applied Biosystems) and according to the protocols supplied. The exon regions sequenced corresponded to National Center for Biotechnology Information MTHFR reference sequences for mRNA (NM.005957) and the corresponding protein (NP.005958) of 656 aa. Sequencing amplicon and probe information is available at [www.ncbi.nlm.nih.gov/genome/probe](http://www.ncbi.nlm.nih.gov/genome/probe) for the following target amplicons: Exon 1 (RSA000045684); Exon 2 (RSA000045680); Exon 3 (RSA000577249); Exon 4 (RSA000045678); Exon 5 (RSA000045676); Exon 6 (RSA001308795); Exon 7 (RSA001253193); Exon 8 (RSA000045669); Exon 9 (RSA000580767); Exon 10 (RSA000580766); and Exon 11 (RSA000580765, RSA000027240). Only the portion of exon 11 that spanned the coding region was sequenced. To ensure high confidence in base calling, only high-quality reads were used for analysis (average QV scores >40 for the region that spanned the target exon; all exons were covered by double-strand reads). Based on these filtering criteria, success rates ranged from 89% to 95% for each exon (Table 1). All sequence information was analyzed by using the SeqScape software suite (Applied Biosystems). As a quality control measure, a subset of base calls were directly verified by TaqMan (Applied Biosystems) allelic-discrimination assays and compared with publicly available genotype data as described (see *Results*).

**Plasmids.** Plasmid pHMTHFR, which carries the 5'-end HA (hemagglutinin A) epitope-tagged human MTHFR ORF under the control of the inducible yeast *GAL1* promoter and the *URA3* selectable marker, was a generous gift of Warren Kruger (Fox Chase Cancer Center, Philadelphia) (22). This plasmid served as the backbone to reconstruct all MTHFR variants by site-directed mutagenesis by using the QuikChange kit (Stratagene). Integrating plasmids containing galactose-inducible MTHFR variants were created by PCR cloning the fragment containing *URA3*, the *GAL1* promoter, and MTHFR coding region from the pHMTHFR-based plasmid into pHO-polyHO (29), which enables targeted integration of this cassette at the *HO* locus.

**Strains.** All haploid yeast strains were *MATa his3 leu2 ura3 lys2* in the S288c background (30). *MATa/MATa* diploid strains were created by mating isogenic *MATa* and *MATa* strains. *fol3Δ::KanMX* and *fol3Δ::KanMX met13Δ::KanMX* strains were obtained by standard mating/sporulation techniques by using strains from the *S. cerevisiae* gene-knockout collection (Invitrogen). Diploids (homozygous or heterozygous for MTHFR variants) were created by mating *fol3Δ::KanMX met13Δ::KanMX* haploids that each contain an integrated version of the *GAL1:MTHFR* variant cassette.

**Growth Conditions.** Synthetic growth media lacking folate was minimal media (31) with Yeast Nitrogen Base without Vitamins (Qbiogene), and all vitamins except folate were added back individually. All *fol3Δ::KanMX* cells were supplemented with 50  $\mu$ g/ml folinic acid (Sigma). For kinetic growth measurements, *fol3Δ::KanMX met13Δ::KanMX* cells were transformed with *GAL1* promoter-driven MTHFR variants and grown to log phase in synthetic galactose medium (2% galactose, 0.1% glucose) supplemented with folinic acid (50  $\mu$ g/ml) and methionine (20  $\mu$ g/ml). Cells were washed three times and aliquoted into 96-well plates containing fresh galactose media with various amounts of folinic acid, but lacking methionine. The volume per well was 200  $\mu$ l with a starting cell density of  $OD_{595} = 0.01$ . Absorbance was tracked every 15–30 min for at least 60 h in a Tecan GENios plate reader at 30°C with no shaking. *MET13* cells used in Fig. 1a were treated the same way except that all growth was in the absence of methionine.

**MTHFR Enzyme Activity Assay.** The assay, which measures the reverse reaction of that catalyzed by MTHFR under physiological conditions, was as described (22) with the following modifications: Yeast extracts were created by bead lysis of 40  $OD_{595}$  cell equivalents (*fol3Δ met13Δ* cells supplemented with folinic acid and methionine) in 350  $\mu$ l of lysis buffer [100 mM sucrose, 50 mM  $KH_2PO_4$  (pH 6.3), and protease inhibitor mixture]. Extracts were clarified by a brief microcentrifugation, and 10–200  $\mu$ g of extract was used to determine the linear range of activity. Radiolabeled substrate (5-[ $^{14}C$ ]MeTHF) was from GE Healthcare Life Sciences. For heat treatment, the reaction mixes without 5-[ $^{14}C$ ]MeTHF were heated to 55°C for the indicated times at which point 5-[ $^{14}C$ ]MeTHF was added back and the reaction proceeded.

**MTHFR Immunoblot Analysis.** Ten  $OD_{595}$  cell equivalents (*fol3Δ met13Δ* cells supplemented with folinic acid and methionine) were extracted in 200  $\mu$ l 0.1 M NaOH for 15 min. SDS sample buffer (50  $\mu$ l) (0.5 M Tris 6.8, 0.4% SDS) was added to supernatants, which were then boiled, clarified, and subject to SDS/PAGE. HA-tagged MTHFR variants were detected on a LI-COR Infrared Imager. Mouse monoclonal anti-HA antibody was from Sigma. Yeast 3-phosphoglycerate kinase (Pgp1k), a loading control, was detected by mouse antibodies generously donated by Jeremy Thorner (University of California, Berkeley, CA).

**ACKNOWLEDGMENTS.** We thank Warren Kruger for human MTHFR plasmids, Jeremy Thorner for anti-yeast PGK antibody, and Dago Dimster-Denk for comments on the manuscript. This work was supported by a University of California Discovery Grant (bio03-10395), the Defense Advanced Research Projects Agency and U.S. Army Research Office Grant W911NF-06-1-0166, and National Institutes of Health Grant GM072859.

- Scriver CR (2001) *The Metabolic and Molecular Bases of Inherited Disease* (McGraw-Hill, New York).
- Ames BN, Elson-Schwab I, Silver EA (2002) High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased  $k_m$ ): Relevance to genetic disease and polymorphisms. *Am J Clin Nutr* 75:616–658.
- Clayton PT (2006) B6-responsive disorders: A model of vitamin dependency. *J Inher Metab Dis* 29:317–326.
- Perez B, et al. (2005) Kinetic and stability analysis of pku mutations identified in bh4-responsive patients. *Mol Genet Metab* 86(Suppl 1):S11–S16.
- Wittung-Stafshede P (2002) Role of cofactors in protein folding. *Acc Chem Res* 35:201–208.
- Frost P, et al. (1995) A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 10:111–113.
- Kim Y-I (2005) 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: A new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. *Nutr Rev* 63:398–407.
- Guenther BD, et al. (1999) The structure and properties of methylenetetrahydrofolate reductase from *Escherichia coli* suggest how folate ameliorates human hyperhomocysteinemia. *Nat Struct Biol* 6:359–365.
- Yamada K, Chen Z, Rozen R, Matthews RG (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. *Proc Natl Acad Sci USA* 98:14853–14858.
- van der Linden IJ, Afman LA, Heil SG, Blom HJ (2006) Genetic variation in genes of folate metabolism and neural-tube defect risk. *Proc Nutr Soc* 65:204–215.
- Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. *Br Med J* 325:1202.
- Bazzano LA, Reynolds K, Holder KN, He J (2006) Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. *J Am Med Assoc* 296:2720–2726.
- Ulrich CM (2005) Nutrigenetics in cancer research—folate metabolism and colorectal cancer. *J Nutr* 135:2698–2702.
- Lewis SJ, Ebrahim S, Davey Smith G (2005) Meta-analysis of mthfr 677c→t polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate? *Br Med J* 331:1053.
- Newton-Cheh C, Hirschhorn JN (2005) Genetic association studies of complex traits: Design and analysis issues. *Mutat Res* 573:54–69.
- Cohen JC, et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. *Science* 305:869–872.
- Romeo S, et al. (2007) Population-based resequencing of angptl4 uncovers variations that reduce triglycerides and increase hdl. *Nat Genet* 39:513–516.
- Vaisse C, et al. (2000) Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. *J Clin Invest* 106:253–262.
- Martin YN, et al. (2006) Human methylenetetrahydrofolate reductase pharmacogenomics: Gene resequencing and functional genomics. *Pharmacogenet Genomics* 16:265–277.
- Livingston RJ, et al. (2004) Pattern of sequence variation across 213 environmental response genes. *Genome Res* 14:1821–1831.
- Glatt CE, et al. (2001) Screening a large reference sample to identify very low frequency sequence variants: Comparisons between two genes. *Nat Genet* 27:435–438.
- Shan X, Wang L, Hoffmaster R, Kruger WD (1999) Functional characterization of human methylenetetrahydrofolate reductase in *Saccharomyces cerevisiae*. *J Biol Chem* 274:32613–32618.
- Cherest H, Thomas D, Surdin-Kerjan Y (2000) Polyglutamylation of folate coenzymes is necessary for methionine biosynthesis and maintenance of intact mitochondrial genome in *Saccharomyces cerevisiae*. *J Biol Chem* 275:14056–14063.
- Rozen R (1997) Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). *Thromb Haemost* 78:523–526.
- Sumner J, Jencks DA, Khani S, Matthews RG (1986) Photoaffinity labeling of methylenetetrahydrofolate reductase with 8-azido-s-adenosylmethionine. *J Biol Chem* 261:7697–7700.
- Yamada K, Strahler JR, Andrews PC, Matthews RG (2005) Regulation of human methylenetetrahydrofolate reductase by phosphorylation. *Proc Natl Acad Sci USA* 102:10454–10459.
- Roje S, et al. (1999) Isolation, characterization, and functional expression of cDNAs encoding nadh-dependent methylenetetrahydrofolate reductase from higher plants. *J Biol Chem* 274:36089–36096.
- Kryukov GV, Pennacchio LA, Sunyaev SR (2007) Most rare missense alleles are deleterious in humans: Implications for complex disease and association studies. *Am J Hum Genet* 80:727–739.
- Voth WP, Richards JD, Shaw JM, Stillman DJ (2001) Yeast vectors for integration at the *HO* locus. *Nucleic Acids Res* 29:e59.
- Brachmann CB, et al. (1998) Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: A useful set of strains and plasmids for PCR-mediated gene disruption and other applications. *Yeast* 14:115–132.
- Sherman F (2002) Getting started with yeast. *Guide to Yeast Genetics and Molecular Biology*, eds Guthrie C, Fink G (Academic, New York), pp 3–41.